Scandinavian ChemoTech AB Series B
Scandinavian ChemoTech AB (publ), a medical technology company, engages in the radiation physics, surgical oncology, and clinical development in Sweden and internationally. It operates in two divisions, Human Care and Animal Care. The company offers IQWave, an electroporation that generates a tumour-specific electrical stimulation; and veterinary medicines under the vetIQur name. Scandinavian Che… Read more
Scandinavian ChemoTech AB Series B (CMOTEC-B) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.550x
Based on the latest financial reports, Scandinavian ChemoTech AB Series B (CMOTEC-B) has a cash flow conversion efficiency ratio of -0.550x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-3.41 Million) by net assets (Skr6.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Scandinavian ChemoTech AB Series B - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Scandinavian ChemoTech AB Series B's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Scandinavian ChemoTech AB Series B Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scandinavian ChemoTech AB Series B ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ANAX Metals Ltd
AU:ANX
|
-0.066x |
|
Agereh Technologies Inc
V:AUTO
|
0.036x |
|
OneMeta AI
OTCQB:ONEI
|
0.093x |
|
DS Sigma Holdings Berhad
KLSE:0269
|
0.043x |
|
Mannatech Incorporated
NASDAQ:MTEX
|
0.347x |
|
Ni Hsin Resources Bhd
KLSE:7215
|
0.000x |
|
DeepSpatial Inc.
PINK:DSAIF
|
0.239x |
|
ARB IOT Group Limited Ordinary Shares
NASDAQ:ARBB
|
-0.019x |
Annual Cash Flow Conversion Efficiency for Scandinavian ChemoTech AB Series B (2014–2024)
The table below shows the annual cash flow conversion efficiency of Scandinavian ChemoTech AB Series B from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr5.98 Million | Skr-13.14 Million | -2.198x | -33.04% |
| 2023-12-31 | Skr11.03 Million | Skr-18.23 Million | -1.652x | -17.77% |
| 2022-12-31 | Skr13.99 Million | Skr-19.63 Million | -1.403x | -74.92% |
| 2021-12-31 | Skr23.92 Million | Skr-19.18 Million | -0.802x | +12.79% |
| 2020-12-31 | Skr9.24 Million | Skr-8.49 Million | -0.920x | +20.30% |
| 2019-12-31 | Skr9.73 Million | Skr-11.23 Million | -1.154x | -416.46% |
| 2018-12-31 | Skr20.50 Million | Skr-4.58 Million | -0.223x | +84.65% |
| 2017-12-31 | Skr10.29 Million | Skr-14.97 Million | -1.456x | -182.40% |
| 2016-12-31 | Skr14.58 Million | Skr-7.52 Million | -0.515x | +5.74% |
| 2015-12-31 | Skr868.64K | Skr-474.99K | -0.547x | +38.15% |
| 2014-12-31 | Skr46.27K | Skr-40.91K | -0.884x | -- |